Earlier today, Santhera and Takeda have announced the extension of their existing commercialization partnership for SNT-MC17 (INN: idebenone) in the European Union and Switzerland to cover the compound's second indication of Duchenne Muscular Dystrophy (DMD).
At 15.00 CET / 14.00 UKT / 09:00 EST, Santhera will host a conference call. People interested in participating may join the teleconference facility using the following dial-in in Switzerland +41 52 267 07 31 (no PIN code needed). The conference call will be recorded for playback and is available one hour after the conference call ends and for 10 days under +41 52 267 07 00, reference number 532083.
Kind regards
Thomas Staffelbach
--------------------------------------------------------------
Santhera Pharmaceuticals (Switzerland) Ltd
Thomas Staffelbach
VP Public and Investor Relations
Hammerstrasse 47
CH - 4410 Liestal
Switzerland
Phone +41 (0)61 906 89 47
Mobile +41 (0)79 541 38 31
Fax +41 (0)61 906 89 41
Santhera Pharmaceuticals (Switzerland) Ltd
Thomas Staffelbach
VP Public and Investor Relations
Hammerstrasse 47
CH - 4410 Liestal
Switzerland
Phone +41 (0)61 906 89 47
Mobile +41 (0)79 541 38 31
Fax +41 (0)61 906 89 41
www.santhera.com
--------------------------------------------------------------
--------------------------------------------------------------